Soluble immune checkpoint molecules in cancer risk, outcomes prediction, and therapeutic applications
Article in Biomarker Research (September 2024)
The most recent citing publications are shown below. View all 20 publications that cite this research output on Dimensions.
The levels of soluble CD137 are increased in tuberculosis patients and associated with disease severity and prognosis
Article in European Journal of Immunology (June 2024)
Soluble levels of 4‐1BB (CD137) and OX40 (CD134) are associated with cancer progression in gastric adenocarcinoma
Article in Journal of Surgical Oncology (June 2024)